Shakil Aslam Biography and Net Worth

Chief Medical Officer of Talphera

Shakil Aslam, MD is a nephrologist with over 20 years of experience in academia, patient care, basic and clinical research and drug and device safety and development. He joined Talphera from BioCryst Pharmaceuticals where he was the Vice President, Clinical Development, Nephrology and Rare Diseases. Dr. Aslam previously held roles at Angion Biomedica, Fresenius Medical Care and Amgen and was an assistant professor at Georgetown University hospital for eleven years with a focus on acute and chronic kidney disease, hypertension, and other kidney diseases. He has authored over two dozen articles in peer-reviewed journals and several book chapters.

What is Shakil Aslam's net worth?: The estimated net worth of Shakil Aslam is at least $96.90 thousand as of February 12th, 2026. Dr. Aslam owns 83,178 shares of Talphera stock worth more than $96,902 as of September 23rd. This net worth estimate does not reflect any other assets that Dr. Aslam may own. Learn More about Shakil Aslam's net worth.
How do I contact Shakil Aslam?: The corporate mailing address for Dr. Aslam and other Talphera executives is 1850 Gateway Drive, Suite 175, San Mateo, CA, 94404. Talphera can also be reached via phone at 650-216-3500 and via email at [email protected]. Learn More on Shakil Aslam's contact information.
Has Shakil Aslam been buying or selling shares of Talphera?: Shakil Aslam has not been actively trading shares of Talphera during the past quarter. Most recently, on Thursday, February 12th, Shakil Aslam bought 35,000 shares of Talphera stock. The stock was acquired at an average cost of $0.81 per share, with a total value of $28,350.00. Following the completion of the transaction, the insider now directly owns 83,178 shares of the company's stock, valued at $67,374.18. Learn More on Shakil Aslam's trading history.
Who are Talphera's active insiders?: Talphera's insider roster includes Raffi Asadorian (CFO), Shakil Aslam (Chief Medical Officer), and Badri Dasu (Chief Engineering Officer). Learn More on Talphera's active insiders.
Are insiders buying or selling shares of Talphera?: In the last year, Talphera insiders bought shares 5 times. They purchased a total of 433,674 shares worth more than $304,347.74. The most recent insider tranaction occured on March, 13th when CEO Vincent J Angotti bought 213,310 shares worth more than $125,852.90. Insiders at Talphera own 3.5% of the company. Learn More about insider trades at Talphera.
Information on this page was last updated on 3/13/2026.

Shakil Aslam Insider Trading History at Talphera

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	35,000	$0.81	$28,350.00	83,178
6/13/2024	Buy	695	$0.98	$681.10	32,695

Shakil Aslam Buying and Selling Activity at Talphera

Talphera Company Overview

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Today's Range

Now: $1.17

$1.15

$1.18

50 Day Range

MA: $1.27

$1.16

$1.47

2 Week Range

Now: $1.17

$0.69

$1.57

Volume

70,738 shs

Average Volume

241,863 shs

Market Capitalization

$60.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69